Cambridge Open Engage home
What is Cambridge Open Engage?
How to Submit
Browse
About
News [opens in a new tab]

Amine-Catalysed Suzuki–Miyaura-Type Coupling? the Identification and Isolation of the Palladium Culprits.

19 March 2021, Version 1

Abstract

A recent report in Nature Catalysis detailed the potentially paradigm-shifting organocatalysis of Suzuki cross-coupling of aryl halides with aryl boronic acids, catalysed by simple amine species. We have conducted a reinvestigation of key claims in this paper across multiple academic and industrial laboratories that shows that the observed catalytic activity cannot be due to the amine, but rather is due to tricyclohexylphosphine palladium complexes that are readily entrained during the purification of the amine.

Keywords

Palladium impurities
amine catalysed Suzuki

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.

Version History

Mar 19, 2021 Version 1

Version Notes

Final version for submission

Metrics

10,065
2,915
1
Views
Downloads

License

CC logo
CC
BY logo
BY
NC logo
NC
ND logo
ND
The content is available under CC BY NC ND 4.0 [opens in a new tab]

DOI

10.26434/chemrxiv.14237288.v1
D O I: 10.26434/chemrxiv.14237288.v1 [opens in a new tab]

Funding

We thank the Chemical Synthesis Centre for Doctoral Training (funded by EPSRC (EP/L015366/1), AstraZeneca, GlaxoSmithKline, Syngenta, UCB, Ziylo and the University of Bristol) for the provision of a PhD studentship (BJSR); the Technology Enhanced Chemical Synthesis Centre for Doctoral Training (funded by EPSRC (EP/S024107/1), AstraZeneca, Astex, Bayer, GlaxoSmithKline, Syngenta, Vertex and the University of Bristol) for the provision of an PhD studentship (JH); GSK (iCASE studentship to MA); the EPSRC (PhD studentship to CSB, EP/T518001/1, project reference 2456710); the UK Catalysis Hub (support provided to RBB, AJJL and RN-S for our membership of the UK Catalysis Hub Consortium, funded by EPSRC grant EP/R027129/1, EP/S018050/1)); the ERC (Advanced Grant 883786 to JC) and the Royal Society (University Research Fellowship to AJJL; Research Fellowship to MOK (UF150536) and equipment grant (RGS\R2\180467)).

Author’s competing interest statement

The authors declare no conflict of interest

Share